ReviewNature reviews. Neurology2013
The spectrum of MOG autoantibody-associated demyelinating diseases.
Review in Nature reviews. Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
163 citing papers in PubMed, 3 syntheses or guidelines pooled it, 372 citations in OpenAlex.
- Clinical Characteristics of Anti-Frontiers in immunology · 2022Pooled it
- Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis.Journal of neurology · 2021Pooled it
- Clinical Features of Coexisting Anti-NMDAR and MOG Antibody-Associated Encephalitis: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders.BioMed research international · 2018Trial
- TRUE-MOGAD Score: A Novel Scoring System to Identify MOGAD Among Positive MOG-IgG Test Results.Neurology(R) neuroimmunology & neuroinflammation · 2026Observational
- Limbic Encephalitis in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2026Review
- A Case Report of Rare MOG Antibody-Associated Optic Neuritis Related to Hepatitis E Virus Infection.Infection and drug resistance · 2026Article
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Pathophysiology, Clinical Patterns, and Therapeutic Challenges of Intractable and Severe Forms.International journal of molecular sciences · 2025Review
- Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as aseptic meningitis and multiple cranial neuritis: a case report.BMC neurology · 2025Article
- Radiological features in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease-diagnostic criteria and lesion dynamics.Pediatric radiology · 2025Review
- Clinical characteristics and factors associated with recurrence and long-term prognosis in patients with MOGAD.Frontiers in immunology · 2025Article
- Morphology of Oligodendroglial Cells.Advances in neurobiology · 2025Review
- Cortical atrophy patterns in myelin oligodendrocyte glycoprotein antibody-associated disease.Annals of clinical and translational neurology · 2024Article
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Complicated by Pachymeningitis: A Case Report.Cureus · 2024Article
- Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management.Antibodies (Basel, Switzerland) · 2024Review
- Article
- Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): contemporary advances and current controversies.Journal of neurology · 2024Review
- FLAIR hyperintense cortical lesions in anti-myelin oligodendrocyte glycoprotein antibody-associated encephalitis with seizure following SARS-CoV-2 mRNA vaccination.eNeurologicalSci · 2024Article
- Proteomic profiling of cerebrospinal fluid in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.World journal of pediatrics : WJP · 2024Article
- Clinical Usefulness of a Cell-based Assay for Detecting Myelin Oligodendrocyte Glycoprotein Antibodies in Central Nervous System Inflammatory Disorders.Annals of laboratory medicine · 2024Article
103 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Myelin oligodendrocyte glycoprotein (MOG) has been identified as a target of demyelinating autoantibodies in animal models of inflammatory demyelinating diseases of the CNS, such as multiple sclerosis (MS). Numerous studies have aimed to establish a role for MOG antibodies in patients with MS, although the results have been controversial. Cell-based immunoassays using MOG expressed in mammalian cells have demonstrated the presence of high-titre MOG antibodies in paediatric patients with acute disseminated encephalomyelitis, MS, aquaporin-4-seronegative neuromyelitis optica, or isolated optic neuritis or transverse myelitis, but only rarely in adults with these disorders. These studies indicate that MOG antibodies could be associated with a broad spectrum of acquired human CNS demyelinating diseases. This Review article discusses the current literature on MOG antibodies, their potential clinical relevance, and their role in the pathogenesis of MOG antibody-associated demyelinating disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.